PLEASANTON, CA--(Marketwire - July 01, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) continues to build on its already extensive HDL Selective Delipidation intellectual property portfolio with the issuance of U.S. Patent No. 7,393,826. This third patent, dated July 1, 2008, further extends the depth of patent coverage surrounding the Company’s HDL Therapy platform, and in particular, the proprietary selective delipidation process. These particular patents are a critical component of the Company’s strategic plan to maximize the value of this strong IP position and the recent clinical trial data to pursue a corporate partnership related to Lipid Sciences’ HDL Selective Delipidation.
